Otros idiomas Ionis Pharmaceuticals, Inc.

Acciones

IONS

US4622221004

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 09/12/2024			Varia. Cinco días.	Varia. 1 de enero.
38,58 ^USD	+1,23 %		+6,87 %	-23,74 %

04/12	Theratechnologies anuncia un acuerdo de licencia exclusiva con Ionis para comercializar Olezarsen y Donidalorsen en Canadá	CI
04/12	Ionis Pharmaceuticals, Inc. Presents at Piper Sandler 36th Annual Healthcare Conference, Dec-04-2024 09:00 AM

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada	04/12
Theratechnologies to Commercialize Two RNA-targeted Medicines in Canada	04/12
Theratechnologies Acquires Canadian Rights to 2 RNA Medicines From Ionis Pharmaceuticals	04/12
Ionis to present at upcoming investor conferences	07/11
Ionis Reports Late-Stage Trial Design in Angelman Syndrome	06/11
Ionis Pharmaceuticals : 3Q24 Earnings Slides	06/11
Ionis Pharmaceuticals, Inc. Updates Earnings Guidance for the Year 2024	06/11
Ionis Pharmaceuticals : reports third quarter 2024 financial results Form 8 K	06/11
Ionis Pharmaceuticals' Q3 Loss Narrows, Revenue Decreases	06/11
Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q3 Revenue $134M	06/11
Ionis Pharmaceuticals: Q3 Earnings Snapshot	06/11
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome	06/11
Ionis reports third quarter 2024 financial results	06/11
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome	06/11
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	06/11
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE	05/11
Ionis Pharmaceuticals Gets FDA Acceptance of New Drug Application for Angioedema Treatment	04/11
Certain warrants of Ionis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2024.	25/10
Certain Restricted Stock Units of Ionis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2024.	25/10
Certain Convertible Notes of Ionis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2024.	25/10
Certain Options of Ionis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2024.	25/10
Certain Common Stock of Ionis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2024.	25/10
Ionis to hold third quarter 2024 financial results webcast	23/10
Ionis Pharmaceuticals - WAINZUA recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis	22/10
Sector Update: Health Care Stocks Lean Lower Premarket Monday	21/10

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Ionis Pharmaceuticals, Inc.

Acciones

IONS

US4622221004

Biotecnología e investigación médica

Otros idiomas

Filtros